Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth

Oncogene volume 24, pages 5384–5388 (2005)Cite this article

Abstract

Ets-1 is the prototype of the family of ETS transcription factors. In human tumors, Ets-1 is expressed in endothelial cells and fibroblasts of the tumor stroma and is proposed to play a role in tumor vascularization and invasion by upregulating expression of matrix-degrading proteases. In human carcinomas, Ets-1 is also expressed by neoplastic cells, but little is known about the functional implications of this observation. We have addressed the role of Ets-1 in epithelial HeLa tumor cells by selecting stably Ets-1 over and underexpressing HeLa cells. Ets-1 expression increases the transformed phenotype of HeLa cells, by promoting cell migration, invasion and anchorage-independent growth, while Ets-1 downregulation reduces cell attachment. In correlation with these results, Ets-1 upregulation increases integrinβ2 expression but not that of other integrins. These results suggest that, in addition to its role in the tumor stroma, Ets-1 may also promote tumor development and progression by increasing neoplastic transformation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Adam M, Schmidt D, Wardelmann E, Wernert N and Albers P . (2003). Eur. Urol., 44, 329–336.

  • Adriaenssens E, Lottin S, Berteaux N, Hornez L, Fauquette W, Fafeur V, Peyrat JP, Le Bourhis X, Hondermarck H, Coll J, Dugimont T and Curgy JJ . (2002). Exp. Cell Res., 275, 215–229.

  • Baker KM, Wei G, Schaffner AE and Ostrowski MC . (2003). J. Biol. Chem., 278, 17876–17884.

  • Behrens P, Mathiak M, Mangold E, Kirdorf S, Wellmann A, Fogt F, Rothe M, Florin A and Wernert N . (2003). Int. J. Cancer, 107, 183–188.

  • Behrens P, Rothe M, Wellmann A, Krischler J and Wernert N . (2001). J. Pathol., 194, 43–50.

  • Block KL, Shou Y and Poncz M . (1996). Blood, 88, 2071–2080.

  • Bottinger EP, Shelley CS, Farokhzad OC and Arnaout MA . (1994). Mol. Cell. Biol., 14, 2604–2615.

  • Bradford AP, Wasylyk C, Wasylyk B and Gutierrez-Hartmann A . (1997). Mol. Cell. Biol., 17, 1065–1074.

  • Danen EH and Yamada KM . (2001). J. Cell. Physiol., 189, 1–13.

  • Dittmer J . (2003). Mol. Cancer, 2, 29.

  • Fafeur V, Tulasne D, Queva C, Vercamer C, Dimster V, Mattot V, Stehelin D, Desbiens X and Vandenbunder B . (1997). Cell. Growth Differ., 8, 655–665.

  • Gilles C, Polette M, Birembaut P, Brunner N and Thompson EW . (1997). Clin. Exp. Metast., 15, 519–526.

  • Graham FL and van der Eb AJ . (1973). Virology, 52, 456–467.

  • Ishii Y, Ogura T, Tatemichi M, Fujisawa H, Otsuka F and Esumi H . (2003). Int. J. Cancer, 103, 161–168.

  • Kumar CC . (1998). Oncogene, 17, 1365–1373.

  • Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S . (1980). Nature, 284, 67–68.

  • Maubant S, Staedel C and Gauduchon P . (2002). Bull. Cancer, 89, 923–934.

  • Maurer P, T'Sas F, Coutte L, Callens N, Brenner C, Van Lint C, de Launoit Y and Baert JL . (2003). Oncogene, 22, 3319–3329.

  • Meraro D, Gleit-Kielmanowicz M, Hauser H and Levi BZ . (2002). J. Immunol., 168, 6224–6231.

  • Nishikawa A, Iwasaki M, Akutagawa N, Manase K, Yamashita S, Endo T and Kudo R . (2000). Gynecol. Oncol., 79, 256–263.

  • Paumelle R, Tulasne D, Kherrouche Z, Plaza S, Leroy C, Reveneau S, Vandenbunder B, Fafeur V and Tulashe D . (2002). Oncogene, 21, 2309–2319.

  • Paumelle R, Tulasne D, Leroy C, Coll J, Vandenbunder B and Fafeur V . (2000). Mol. Biol. Cell, 11, 3751–3763.

  • Peterson EJ . (2003). Immunol. Rev., 192, 113–121.

  • Petrella A, Doti I, Agosti V, Giarrusso PC, Vitale D, Bond HM, Cuomo C, Tassone P, Franco B, Ballabio A, Venuta S and Morrone G . (1998). Blood, 91, 4554–4560.

  • Pourtier-Manzanedo A, Vercamer C, Van Belle E, Mattot V, Mouquet F and Vandenbunder B . (2003). Oncogene, 22, 1795–1806.

  • Ruoslahti E . (1991). J. Clin. Invest., 87, 1–5.

  • Sato Y . (1998). Hum. Cell., 11, 207–214.

  • Schwartz MA and Assoian RK . (2001). J. Cell. Sci., 114, 2553–2560.

  • Seth A and Papas TS . (1990). Oncogene, 5, 1761–1767.

  • Tajima A, Miyamoto Y, Kadowaki H and Hayashi M . (2000). Biochim. Biophys. Acta, 1492, 377–384.

  • Vandenbunder B, Pardanaud L, Jaffredo T, Mirabel MA and Stehelin D . (1989). Development, 107, 265–274.

  • Waga K, Nakamura Y, Maki K, Arai H, Yamagata T, Sasaki K, Kurokawa M, Hirai H and Mitani K . (2003). Oncogene, 22, 59–68.

  • Wasylyk B, Hahn SL and Giovane A . (1993). Eur. J. Biochem., 211, 7–18.

  • Wasylyk C, Schlumberger SE, Criqui-Filipe P and Wasylyk B . (2002). Mol. Cell. Biol., 22, 2687–2702.

  • Wernert N . (1997). Virchows Arch., 430, 433–443.

  • Wernert N, Gilles F, Fafeur V, Bouali F, Raes MB, Pyke C, Dupressoir T, Seitz G, Vandenbunder B and Stehelin D . (1994). Cancer Res., 54, 5683–5688.

  • Wernert N, Raes MB, Lassalle P, Dehouck MP, Gosselin B, Vandenbunder B and Stehelin D . (1992). Am. J. Pathol., 140, 119–127.

  • Wernert N, Stanjek A, Kiriakidis S, Hügel A, Jha HC, Mazitschek R and Giannis A . (1999). Angew. Chem., 38, 3228–3231.

Download references

Acknowledgements

We are indebted to Dr Hiroyasu Esumi (National Cancer Center Research Institute East, Kashiwa, Chiba/Japan) for providing plasmids. This work has been supported by German Cancer Association (‘Deutsche Krebshilfe’ Grant no. 10-1610-We2) and DFG (‘Deutsche Forschungsgemeinschaft’ Grant no. We 1104/8-1).

Author information

Author notes

  1. Ali Fuat Okuducu

    Present address: Institute of Neuropathology, Charité, Campus Virchow Klinikum, Humboldt University, Augustenbergerplatz 1, 13353, Berlin, Germany

Authors and Affiliations

  1. Institute of Pathology, University of Bonn, PO Box 2120, Bonn, 53011, Germany

    Jens Claus Hahne, Ali Fuat Okuducu, Annette Kaminski, Alexandra Florin & Nicolas Wernert

  2. CNRS UMR8526, Institut de Biologie de Lille, 1 rue Calmette, Lille Cedex, 59021, France

    Fabrice Soncin

Authors
  1. Jens Claus Hahne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ali Fuat Okuducu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Annette Kaminski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandra Florin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fabrice Soncin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicolas Wernert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolas Wernert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hahne, J., Okuducu, A., Kaminski, A. et al. Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene 24, 5384–5388 (2005). https://doi.org/10.1038/sj.onc.1208761

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208761

Keywords

This article is cited by

Search

Advanced search

Quick links